Inhibitory effect of FSLLRY-NH2 on inflammatory responses induced by hydrogen peroxide in HepG2 cells
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Yeon Joo | - |
dc.contributor.author | Kim, Su Jin | - |
dc.contributor.author | Kwon, Kyoung Wan | - |
dc.contributor.author | Lee, Won Mo | - |
dc.contributor.author | Im, Wi Joon | - |
dc.contributor.author | Sohn, Uy Dong | - |
dc.date.available | 2019-03-08T08:37:44Z | - |
dc.date.issued | 2017-07 | - |
dc.identifier.issn | 0253-6269 | - |
dc.identifier.issn | 1976-3786 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/4300 | - |
dc.description.abstract | Proteinase activated receptor 2 (PAR2), which is localized in the GI tract, the respiratory system, and the kidney tubules is a G protein-coupled receptor associated with inflammation, metabolism, and disease. The aim of this study was to explore the role of PAR2 in hydrogen peroxide (H2O2)-induced HepG2 cells by using FSLLRY-NH2 a PAR2 antagonist. H2O2 treatment resulted in induction of PAR2 in esophageal, gastric, and liver cells, with the most robust response being in HepG2 cells. Furthermore, this effect was dose-dependent in HepG2 cells. Treatment with H2O2 at concentrations above 400 mu M for 24 h also reduced HepG2 cell viability. H2O2 treatment increased both the protein and mRNA levels of IL-1 beta, IL-8, and TNF-alpha, as well as those of SAPK/JNK. The increased levels of these pro-inflammatory genes and SAPK/JNK induced by H2O2 were attenuated in a dose-dependent manner when cells were co-treated with H2O2 and FSLLRY-NH2. In summary, the PAR2 antagonist peptide, FSLLRY-NH2, reduces the level of the pro-inflammatory genes IL-8, IL-1 beta, and TNF-alpha induced by H2O2, through the SAPK/JNK pathways in HepG2 cells. These data suggest that a PAR2 antagonist could be an anti-inflammatory agent in HepG2 cells. | - |
dc.format.extent | 10 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | PHARMACEUTICAL SOC KOREA | - |
dc.title | Inhibitory effect of FSLLRY-NH2 on inflammatory responses induced by hydrogen peroxide in HepG2 cells | - |
dc.type | Article | - |
dc.identifier.doi | 10.1007/s12272-017-0927-9 | - |
dc.identifier.bibliographicCitation | ARCHIVES OF PHARMACAL RESEARCH, v.40, no.7, pp 854 - 863 | - |
dc.identifier.kciid | ART002248660 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000406746100007 | - |
dc.identifier.scopusid | 2-s2.0-85021150854 | - |
dc.citation.endPage | 863 | - |
dc.citation.number | 7 | - |
dc.citation.startPage | 854 | - |
dc.citation.title | ARCHIVES OF PHARMACAL RESEARCH | - |
dc.citation.volume | 40 | - |
dc.type.docType | Article | - |
dc.publisher.location | 대한민국 | - |
dc.subject.keywordAuthor | HepG2 | - |
dc.subject.keywordAuthor | FSLLRY-NH2 | - |
dc.subject.keywordAuthor | PAR2 | - |
dc.subject.keywordAuthor | PAR2 antagonist | - |
dc.subject.keywordPlus | PROTEASE-ACTIVATED RECEPTORS | - |
dc.subject.keywordPlus | COUPLED RECEPTORS | - |
dc.subject.keywordPlus | EPITHELIAL-CELLS | - |
dc.subject.keywordPlus | PARACELLULAR PERMEABILITY | - |
dc.subject.keywordPlus | 7-TRANSMEMBRANE RECEPTORS | - |
dc.subject.keywordPlus | ENDOTHELIAL-CELLS | - |
dc.subject.keywordPlus | KINASE PATHWAY | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordPlus | AGONISTS | - |
dc.subject.keywordPlus | MECHANISMS | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Medicinal | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.